448 related articles for article (PubMed ID: 29605624)
1. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.
Calverley PMA; Anzueto AR; Carter K; Grönke L; Hallmann C; Jenkins C; Wedzicha J; Rabe KF
Lancet Respir Med; 2018 May; 6(5):337-344. PubMed ID: 29605624
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
[TBL] [Abstract][Full Text] [Related]
3. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
[TBL] [Abstract][Full Text] [Related]
4. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
Buhl R; Magder S; Bothner U; Tetzlaff K; Voß F; Loaiza L; Vogelmeier CF; McGarvey L
Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
Ichinose M; Taniguchi H; Takizawa A; Grönke L; Loaiza L; Voß F; Zhao Y; Fukuchi Y
Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
Derom E; Brusselle GG; Joos GF
Int J Chron Obstruct Pulmon Dis; 2016; 11():3163-3177. PubMed ID: 28008243
[TBL] [Abstract][Full Text] [Related]
7. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
[TBL] [Abstract][Full Text] [Related]
8. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
[TBL] [Abstract][Full Text] [Related]
9. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
[TBL] [Abstract][Full Text] [Related]
10. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
Maltais F; O'Donnell D; Gáldiz Iturri JB; Kirsten AM; Singh D; Hamilton A; Tetzlaff K; Zhao Y; Casaburi R
Ther Adv Respir Dis; 2018; 12():1753465818755091. PubMed ID: 29439648
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
Ferguson GT; Fležar M; Korn S; Korducki L; Grönke L; Abrahams R; Buhl R
Adv Ther; 2015 Jun; 32(6):523-36. PubMed ID: 26112656
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO
Wedzicha JA; Buhl R; Singh D; Vogelmeier CF; de la Hoz A; Xue W; Anzueto A; Calverley PMA
Adv Ther; 2020 Oct; 37(10):4266-4279. PubMed ID: 32776202
[TBL] [Abstract][Full Text] [Related]
13. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
Singh D; Ferguson GT; Bolitschek J; Grönke L; Hallmann C; Bennett N; Abrahams R; Schmidt O; Bjermer L
Respir Med; 2015 Oct; 109(10):1312-9. PubMed ID: 26320402
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study.
Kawachi S; Fujimoto K
Int J Chron Obstruct Pulmon Dis; 2019; 14():1167-1176. PubMed ID: 31213796
[No Abstract] [Full Text] [Related]
15. Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD.
Maltais F; Hamilton A; Voß F; Maleki-Yazdi MR
Adv Ther; 2019 Apr; 36(4):962-968. PubMed ID: 30843141
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
Moretz C; Bengtson LG; Sharpsten L; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():2047-2060. PubMed ID: 31564852
[TBL] [Abstract][Full Text] [Related]
17. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
Aalbers R; Maleki-Yazdi MR; Hamilton A; Waitere-Wijker S; Zhao Y; Amatto VC; Schmidt O; Bjermer L
Adv Ther; 2015 Sep; 32(9):809-22. PubMed ID: 26404912
[TBL] [Abstract][Full Text] [Related]
18. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
[TBL] [Abstract][Full Text] [Related]
19. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
[TBL] [Abstract][Full Text] [Related]
20. Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.
Muruganandan S; Jayaram L
Int J Chron Obstruct Pulmon Dis; 2015; 10():1179-89. PubMed ID: 26124657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
